Sarvan Maddipatla
Overview
Explore the profile of Sarvan Maddipatla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
6
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maddipatla S, Agnivesh P, Bakchi B, Nanduri S, Kalia N, Yaddanapudi V
Mol Divers
. 2025 Mar;
PMID: 40085403
This study addresses the urgent need for new drugs to combat multi-drug-resistant tuberculosis (MDR-TB). Focusing on MmpL3, a protein essential for mycobacterial cell wall synthesis, we designed and synthesised 50...
2.
Bandela R, Sahoo S, Mukhopadhyay A, Imran M, Imran M, Singampalli A, et al.
ChemMedChem
. 2024 Dec;
e202400902.
PMID: 39734278
The continued prevalence of drug-resistant Mycobacterium tuberculosis (Mtb) strains, particularly against first-line antitubercular (anti-TB) drugs, presents an impending public health threat that necessitates the exploration and development of New Chemical...
3.
Maddipatla S, Bakchi B, Shinde M, Bonardi A, Raman P, Bhalerao H, et al.
Arch Pharm (Weinheim)
. 2024 Dec;
358(1):e2400482.
PMID: 39686882
Carbonic anhydrases (CAs) are crucial in regulating various physiological processes in the body. The overexpression of isoforms human carbonic anhydrases (hCA) IX and hCA XII is linked to tumour progression....
4.
Bakchi B, Devabattula G, Maddipatla S, Singampalli A, Kumar Porna D, Nanduri S, et al.
ChemMedChem
. 2024 Nov;
20(5):e202400817.
PMID: 39523484
A facile multicomponent synthesis of new indole-based phenylthiazolyl-dihydropyrazolone hybrids, their structural characterization, biological evaluation, and in silico investigations as anticancer agents are reported. Lead molecule 5 i of the series...
5.
Bakchi B, Maddipatla S, Gupta K, Singampalli A, Saxena D, Maitra R, et al.
Arch Pharm (Weinheim)
. 2024 Aug;
357(11):e2400358.
PMID: 39102220
The escalating severity of the menace posed by bacterial resistance has rendered the existing antibiotics less effective, thus necessitating the discovery of new antibacterial agents. The current study reports the...
6.
Maddipatla S, Bakchi B, Gadhave R, Ammara A, Sau S, Rani B, et al.
Arch Pharm (Weinheim)
. 2024 Mar;
357(7):e2400064.
PMID: 38498883
With the rise of multidrug-resistant tuberculosis, the imperative for an alternative and superior treatment regimen, incorporating novel mechanisms of action, has become crucial. In pursuit of this goal, we have...
7.
Patil S, Sandeep Chary P, Maddipatla S, Madhavi Y, Singothu S, Bhandari V, et al.
J Biomol Struct Dyn
. 2024 Jan;
:1-18.
PMID: 38247232
Cyclodextrin complexes loaded with venetoclax for improved solubility and therapeutic efficacy as repurposed drug. The venetoclax-cyclodextrin inclusion complex was prepared using kneading method. Primarily in-silico molecular docking study was performed...
8.
Sahoo S, Ommi O, Maddipatla S, Singh P, Ahmad M, Kaul G, et al.
Mol Divers
. 2022 Oct;
27(5):2037-2052.
PMID: 36282413
In our continued efforts to find potential chemotherapeutics active against drug-resistant (DR) Mycobacterium tuberculosis (Mtb), causative agent of Tuberculosis (TB) and to curb the current burdensome treatment regimen, herein we...
9.
Sahoo S, Maddipatla S, Gajula S, Ahmad M, Kaul G, Nanduri S, et al.
Bioorg Med Chem
. 2022 Apr;
64:116777.
PMID: 35487101
Ever increasing drug resistance has become an impeding threat that continues to hamper effective tackling of otherwise treatable tuberculosis (TB). Such dismal situation necessitates identification and exploration of multitarget acting...